Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HK2 | P52789 | 5/20 | 0.45 |
| ▸ | HK1 | P19367 | 4/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.37 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | PYGB | P11216 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20657365 | 1.00 | KDM4E (0.48) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL28461019 | 1.00 | KDM4E (0.48) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL1085802 | 0.86 | KDM4E (0.46) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL24651209 | 0.78 | ALDH1A1 (0.40) | MAPK1CA1CA2CA9LGALS8 | |
| SCHEMBL28081071 | 0.77 | KDM4E (0.44) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL10344862 | 0.76 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL10325486 | 0.76 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL28919637 | 0.76 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL10325207 | 0.76 | KDM4E (0.49) | KDM4ELMNACYP2D6CYP2C19HK2 | |
| SCHEMBL16580127 | 0.75 | KDM4E (0.51) | KDM4ELMNACYP2D6CYP2C19HK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021076886-A1 | 3-PHENYLSULPHONYL-QUINOLINE DERIVATIVES AS AGENTS FOR TREATING PATHOGENIC BLOOD VESSELS DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-04-22 | — | — | WO | disclosed |
| US-9162986-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS LLC (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS LLC | 2014-12-25 | — | — | US | disclosed |
| EP-2176276-B1 | DERIVATIVES OF NYSTATIN AND THEIR USE AS ANTIFUNGAL AGENTS | BIOSERGEN AS (NO) | 2014-07-30 | — | — | EP | disclosed |
| US-8778625-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140031534-A1 | COMPOUNDS | BIOSERGEN AS (NO) | 2014-01-30 | — | — | US | disclosed |
| US-8415312-B2 | Compound which is a nystatin derivative | BIOSERGEN AS (NO) | 2013-04-09 | — | — | US | disclosed |
| US-8415312-B2 | Compound which is a nystatin derivative | BIOSERGEN AS (NO) | 2013-04-09 | — | — | US | disclosed |
| US-8299110-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors | PHARMACYCLICS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110269806-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20100286077-A1 | COMPOUNDS | BIOSERGEN AS (NO) | 2010-11-11 | — | — | US | disclosed |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | PHARMACYLICS, INC. A DELAWARE CORPORATION (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2004037159-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING FAT METABOLISM | OBETHERAPY BIOTECHNOLOGY (FR) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031534-A1 | COMPOUNDS | MYC, C9, MYCBP | KDM4E 4203/4885LMNA 1086/4885CYP2D6 3534/4885 |
| US-20100286077-A1 | COMPOUNDS | C9, ERG28, NISCH | KDM4E 4212/4885LMNA 1004/4885CYP2D6 2031/4885 |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | F13B, HABP2, F7 | KDM4E 561/4885LMNA 478/4885CYP2D6 1530/4885 |
| US-20110269806-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | F13B, HABP2, F7 | KDM4E 561/4885LMNA 478/4885CYP2D6 1530/4885 |
| US-20090054432-A1 | 2-(2-Hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-Carboxamidine Derivatives as Factor VIIA Inhibitors | F13B, HABP2, F7 | KDM4E 561/4885LMNA 478/4885CYP2D6 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.